The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PRQR | -45.45% | -46.93% | -11.89% | -85% |
| S&P | +12.57% | +87.93% | +13.44% | +235% |
ProQR Therapeutics NV is a clinical stage biopharmaceutical company. It is engaged in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases, such as Leber congenital amaurosis 10, Usher syndrome type 2, and autosomal dominant retinitis pigmentosa. Its product pipeline includes Sepofarsen, Ultevursen, Axiomer technology, and RNA therapy. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.
The clinical-stage biotech released fourth-quarter and full-year earnings.
Analysts are notably more bearish on the company following unhappy news about its leading drug candidate.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $3.37M | -20.2% |
| Gross Profit | $2.58M | -25.5% |
| Gross Margin | 76.72% | -5.4% |
| Market Cap | $224.10M | 50.8% |
| Market Cap / Employee | $1.35M | 0.0% |
| Employees | 166.1 | 6.1% |
| Net Income | -$12.86M | -44.4% |
| EBITDA | -$12.44M | -38.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $125.59M | 25.9% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $11.77M | -8.3% |
| Short Term Debt | $5.37M | 12.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -35.58% | -16.3% |
| Return On Invested Capital | -47.35% | 4.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$15.44M | -119.9% |
| Operating Free Cash Flow | -$15.23M | -127.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 7.76 | 1.49 | 2.52 | 2.85 | -46.48% |
| Price to Sales | 12.52 | 6.88 | 12.00 | 13.16 | 71.50% |
| Price to Tangible Book Value | 7.76 | 1.49 | 2.52 | 2.85 | -46.48% |
| Price to Free Cash Flow TTM | 7.16 | - | |||
| Enterprise Value to EBITDA | -11.50 | -1.22 | -6.91 | -9.32 | 25.71% |
| Free Cash Flow Yield | 14.0% | - | |||
| Return on Equity | -43.7% | -52.6% | -76.0% | -99.5% | 47.08% |
| Total Debt | $16.08M | $16.31M | $17.65M | $17.14M | -2.69% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
